Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01218854
Other study ID # 100217
Secondary ID 10-CC-0217
Status Completed
Phase Phase 1
First received
Last updated
Start date March 20, 2012
Est. completion date November 16, 2016

Study information

Verified date May 28, 2024
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: - Currently, standard procedures for biopsies that are guided by computed tomography (CT) imaging involve CT scans and a computer program to plan and illustrate where the physician will place the needle to obtain the required cells or tissue. Inserting the biopsy needle at the planned angle is not an easy task, because the appropriate angle of insertion must be estimated based on prior experience. Researchers are studying experimental techniques that might provide better guidance about the right angle to insert the biopsy needle and thereby improve the collection of the appropriate biopsy cells or tissue. Objectives: - To evaluate the effectiveness of two biopsy needle guidance methods in CT-guided tissue biopsy. Eligibility: - Individuals at least 18 years of age who are scheduled to have CT-guided tissue biopsy. Design: - Participants will have a tissue biopsy guided by CT scans and either a laser system or a plastic block to illustrate the appropriate angle of insertion. The skin will be numbed with anesthetic to minimize discomfort during the procedure. - Before inserting the biopsy needle, the study physician will hold the needle in place so that a Food and Drug Administration-approved medical GPS (electromagnetic tracking) system can measure the needle angle as it enters the tissue. - After the needle angle data has been collected, researchers will proceed with the actual biopsy procedure as it would normally occur, using standard methods. - No additional treatment will be provided as part of this protocol.


Description:

Background: - Currently, standard/conventional CT-guided biopsies proceed as follows the physician: 1. obtains a pre-procedural CT scan, 2. plans the needle s angle based on this CT scan, 3. selects the angle at which the needle should be inserted based on the pre-procedural CT scan, 4. inserts the needle while aiming to replicate that planned needle angle by using only their visual-spatial abilities, and 5. re-images the patient to confirm needle location followed by needle repositioning, if needed. - Improving upon these standard methods of needle placement could have widespread benefits (e.g. improved diagnostic tissue sampling, decreased needle repositionings, etc.) We will be studying three needle angle selection systems. The laser-assisted needle angle selection system or LNASS, is a custom fabricated device that uses a Class II pointer similar to ones used for pointing at slides during lectures. Objectives: - To compare the angle difference between L-NASS (Method A) and the standard method (clinician intuition/conventional method) - To compare the angle difference between B-NASS (Method B) and the standard method (clinician intuition) - To compare the angle difference between the mobile device-NASS or MD-NASS (C) and the standard method (clinician intuition/conventional method) Eligibility: - Ages Eligible for Study: 18 Years and older - Genders Eligible for Study: Both - Inclusion: - Must be undergoing a scheduled CT-guided biopsy. - Must have ability to follow breathing instructions like holding breath (if procedure is to be performed without general anesthesia). - Exclusion: - No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation. - Any known allergy to plastics or polymers (since the Ultem polymer could theoretically induce a rash in these patients, even though it is hypoallergenic). - Pacemakers or automatic implantable cardiac defibrillators. - Gross body weight above the CT table limit (450 pounds). Design: - Primary outcome measure for the first arm is: --The difference between planned and achieved needle angle of a laser-assisted needle angle selection system with the standard method (clinician s intuition or conventional method) of CT-guided biopsy. - Primary outcome measure for the second arm is: --The difference between planned and achieved needle angle of a block with pre-drilled needle angles with the standard method (clinician s intuition or conventional method) of CT-guided biopsy - Primary outcome for the third arm is: --The difference between planned and achieved needle angle of a mobile device-assisted needle angle selection system with the standard method (clinician's intuition or conventional method) of CT-guided biopsy. - The tool for measuring the needle angles will be an FDA-approved electromagnetic tracking system, which tracks needle movement and position. - These comparisons will be done as a bystander study. - Needle guidance system will only be used initially to select the angle during a superficial, shallow needle insertion at the skin surface (less than 1 cm deep). - At no time will the needle enter tissue that it wouldn t have otherwise entered as none of the system will be used to perform the biopsies at this time. - The key portions of the procedure will not be altered in any substantive way.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date November 16, 2016
Est. primary completion date November 16, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - INCLUSION CRITERIA: Patients must fulfill all of the following criteria to be eligible for study admission: - All patients must be undergoing a CT-guided biopsy. - Age greater than 18 years. - No serious concurrent medical illness that would preclude the patient from making a rational informed decision on participation. - The ability to understand and willingness to sign a written informed consent form, and to comply with the protocol. If in question, an ethics consult will be obtained. - Ability to follow breathing instructions like holding breath (if procedure is to be performed without general anesthesia). - Patients must be actively enrolled on an NIH protocol and be scheduled for a CT-guided biopsy. EXCLUSION CRITERIA: - Patients with an altered mental status that precludes understanding or consenting for the biopsy procedure will be excluded from this study. - Patients unlikely to be able to hold reasonably still on a procedure table for the length of the procedure. - Patients with any known allergy to plastics or polymers (since the Ultem -polymer could theoretically induce a rash in these patients, even though it is hypoallergenic). - Inability to follow breathing instructions, if without general anesthesia. - Patients with pacemakers or automatic implantable cardiac defibrillators. - Gross body weight above the CT table limit (450 pounds).

Study Design


Intervention

Device:
Needle angle measurement
The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institutes of Health Clinical Center (CC)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Jacobi V, Thalhammer A, Kirchner J. Value of a laser guidance system for CT interventions: a phantom study. Eur Radiol. 1999;9(1):137-40. doi: 10.1007/s003300050644. — View Citation

Miaux Y, Guermazi A, Gossot D, Bourrier P, Angoulvant D, Khairoune A, Turki C, Bouche E. Laser guidance system for CT-guided procedures. Radiology. 1995 Jan;194(1):282-4. doi: 10.1148/radiology.194.1.7997570. — View Citation

Pereles FS, Baker M, Baldwin R, Krupinski E, Unger EC. Accuracy of CT biopsy: laser guidance versus conventional freehand techniques. Acad Radiol. 1998 Nov;5(11):766-70. doi: 10.1016/s1076-6332(98)80260-2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Difference between L-NASS and standard method Data is currently undergoing analysis Completion of study
Primary Differnce between B-NASS and standard method Data is currently undergoing analysis Completion of study
Primary The difference between MD-NASS and standard method Data is currently undergoing analysis Completion of study
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients